Loading data for MGX — first visit, this takes a few seconds.

Metagenomi Therapeutics, Inc. (MGX)

NasdaqGS: MGX · Real-Time Price · USD

1.17

+0.01 (0.86%)

At close: Sep 04, 2026, 8:00 PM

1.17

+0.00%

After-hours: 4:10 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	0.84
Market Cap	44.2M
Revenue (ttm)	13.6M
Net Income (ttm)	-93.5M
	0.67
	-2.49
	n/a
	-0.64
P/B (ttm)	0.39
P/S (ttm)	3.26
Earnings Date	Aug 13, 2025

Ask	1.48
Volume	38,503
Avg. Volume (20D)	160,796
Open	1.14
Previous Close	1.16
Day's Range	1.14 - 1.17
52-Week Range	1.13 - 3.95
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About MGX

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyret...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 9, 2024

Employees 113

Stock Exchange NasdaqGS

Ticker Symbol MGX

Website https://metagenomi.co

Full Company Profile

Financial Performance

In 2025, Metagenomi Therapeutics's revenue was 25.21M, a decrease of -51.79% compared to the previous year's 52.3M. Earnings were -87.87M, an increase of 12.57%.

Financial Statements

Earnings Surprise

Metagenomi Therapeutics has released their quarterly earnings on Aug 10, 2026:

Revenue of $1.25M misses estimates by $0, with -69.76% YoY decline.
EPS of -0.73 misses estimates by -0.21, with -35.19% YoY decline.

Next Earnings Release

Metagenomi Therapeutics, Inc. is scheduled to release its earnings on Aug 13, 2025, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · Zacks

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -15.87% and -120.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

4 weeks ago · Zacks

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +37.88% and +1.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 month ago · Zacks

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 months ago · Simply Wall St.

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ) missed earnings with its latest first-quarter results, disappointing...

3 months ago · Zacks

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -2.52% and -68.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock...

Page 1 of 2

Metagenomi Therapeutics, Inc. (MGX)